SI2089031T1 - Zmanjšanje prekomerne teže ali debelosti - Google Patents

Zmanjšanje prekomerne teže ali debelosti

Info

Publication number
SI2089031T1
SI2089031T1 SI200730517T SI200730517T SI2089031T1 SI 2089031 T1 SI2089031 T1 SI 2089031T1 SI 200730517 T SI200730517 T SI 200730517T SI 200730517 T SI200730517 T SI 200730517T SI 2089031 T1 SI2089031 T1 SI 2089031T1
Authority
SI
Slovenia
Prior art keywords
reduction
overweight
obesity
weight gain
bgp
Prior art date
Application number
SI200730517T
Other languages
English (en)
Inventor
Nagy Peter Literati
Zoltan Szilvassy
Kalman Tory
Laszlo Vigh
Kalman Takacs
Jozsef Mandl
Balazs Sumegi
Sandor Bernath
Attila Kolonics
Gabor Balogh
Janos Egri
Original Assignee
N Gene Res Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by N Gene Res Lab Inc filed Critical N Gene Res Lab Inc
Publication of SI2089031T1 publication Critical patent/SI2089031T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Fats And Perfumes (AREA)
  • Pyridine Compounds (AREA)
SI200730517T 2006-11-02 2007-07-23 Zmanjšanje prekomerne teže ali debelosti SI2089031T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US85611706P 2006-11-02 2006-11-02
US11/687,945 US7763601B2 (en) 2006-11-02 2007-03-19 Prevention and treatment of obesity
EP07766498A EP2089031B1 (en) 2006-11-02 2007-07-23 Reduction of overweight or obesity
PCT/HU2007/000066 WO2008053256A1 (en) 2006-11-02 2007-07-23 Reduction of overweight or obesity

Publications (1)

Publication Number Publication Date
SI2089031T1 true SI2089031T1 (sl) 2011-04-29

Family

ID=38592002

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200730517T SI2089031T1 (sl) 2006-11-02 2007-07-23 Zmanjšanje prekomerne teže ali debelosti

Country Status (20)

Country Link
US (1) US7763601B2 (sl)
EP (1) EP2089031B1 (sl)
JP (1) JP2010509199A (sl)
KR (1) KR20090082442A (sl)
AT (1) ATE489090T1 (sl)
AU (1) AU2007315931A1 (sl)
BR (1) BRPI0717867A2 (sl)
CA (1) CA2668382A1 (sl)
DE (1) DE602007010819D1 (sl)
DK (1) DK2089031T3 (sl)
HK (1) HK1131737A1 (sl)
HR (1) HRP20110023T1 (sl)
IL (1) IL198296A (sl)
MX (1) MX2009004538A (sl)
NO (1) NO20092025L (sl)
PL (1) PL2089031T3 (sl)
PT (1) PT2089031E (sl)
RU (1) RU2443417C2 (sl)
SI (1) SI2089031T1 (sl)
WO (1) WO2008053256A1 (sl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
EP3788877A1 (en) * 2007-04-11 2021-03-10 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
WO2009074835A1 (en) * 2007-12-10 2009-06-18 N-Gene Research Laboratories Inc. Dose reduction of a cannabinoid cb1 receptor antagonist in the treatment of overweight or obesity
HUP1100444A2 (en) 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
HUP1100445A2 (en) 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
HUP1800298A1 (hu) 2018-08-30 2020-05-28 N Gene Res Laboratories Inc Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4187220A (en) 1977-08-30 1980-02-05 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara R.T. New O-(3-amino-2-hydroxy-propyl)-amidoxime derivatives, process for the preparation thereof and pharmaceutical compositions containing same
US4287220A (en) * 1980-02-19 1981-09-01 Frito-Lay, Inc. Hull containing compositions
HU207988B (en) * 1988-10-20 1993-07-28 Biorex Kutato Fejlesztoe Kft Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components
HU9502843D0 (en) 1995-09-29 1995-11-28 Livigene Ltd Pharmaceutical composition
US6884424B2 (en) 1995-12-22 2005-04-26 N-Gene Research Laboratories Inc. Method for treating the pathological lesions of the skin that develop by ultraviolet radiation of the sunlight
US6458371B1 (en) 1995-12-22 2002-10-01 Medgene, Limited Cosmetic composition and a method for the prevention and/or reduction of the photoaging processes of the skin
HU9701081D0 (en) 1997-06-23 1997-08-28 Gene Research Lab Inc N Pharmaceutical composition of antitumoral activity
HUP9701080A3 (en) 1997-06-23 1999-05-28 Gene Res Lab Inc New York N Pharmaceutical composition containing a compound of antiviral activity and a hydroximic acid ester derivative
AU5296799A (en) 1998-08-03 2000-02-28 N-Gene Kutato Kft. Pharmaceutical compositions against autoimmune diseases
UA65635C2 (uk) * 1998-09-03 2004-04-15 Н-Гене Кутато Кфт. НЕНАСИЧЕНІ ПОХІДНІ ГІДРОКСИМОВОЇ КИСЛОТИ, ЩО МАЮТЬ ВЛАСТИВОСТІ ІНГІБІТОРІВ NAD<sup>+</sup>-ADP-РИБОЗИЛТРАНСФЕРАЗИ
CA2452558C (en) 2001-07-17 2009-12-22 N-Gene Research Laboratories Inc. A synergistic pharmaceutical combination for the prevention or treatment of diabetes
HUP0401177A2 (en) 2004-06-14 2007-09-28 N Gene Res Lab Inc Pharmaceutical composition for increasing the mitochondrial genesis
HUP0401176A2 (en) 2004-06-14 2007-09-28 N Gene Res Lab Inc Pharmaceutical composition having prpkinetic effect
HUP0500145A2 (en) 2005-01-28 2006-11-28 Gene Res Lab N Use of o-(3-piperidino-2-hydroxy-1-propyl)-nicotinic amidoxime for preparation of medicaments against oral diseases
CN101534836B (zh) 2006-09-05 2011-09-28 彼帕科学公司 Parp抑制剂在制备治疗肥胖症的药物中的用途

Also Published As

Publication number Publication date
EP2089031A1 (en) 2009-08-19
IL198296A (en) 2011-09-27
BRPI0717867A2 (pt) 2013-10-29
WO2008053256A1 (en) 2008-05-08
PT2089031E (pt) 2011-02-24
NO20092025L (no) 2009-06-02
EP2089031B1 (en) 2010-11-24
DK2089031T3 (da) 2011-02-14
KR20090082442A (ko) 2009-07-30
ATE489090T1 (de) 2010-12-15
DE602007010819D1 (de) 2011-01-05
MX2009004538A (es) 2009-05-22
IL198296A0 (en) 2010-02-17
US7763601B2 (en) 2010-07-27
RU2443417C2 (ru) 2012-02-27
PL2089031T3 (pl) 2011-05-31
AU2007315931A1 (en) 2008-05-08
HK1131737A1 (en) 2010-02-05
CA2668382A1 (en) 2008-05-08
JP2010509199A (ja) 2010-03-25
RU2009119567A (ru) 2010-12-10
US20080108673A1 (en) 2008-05-08
HRP20110023T1 (hr) 2011-04-30

Similar Documents

Publication Publication Date Title
HK1131737A1 (en) Reduction of overweight or obesity
EP1730163A4 (en) Pharmaceutical salts of 3-O- (3,3-dimethylsuccinyl) betulinic acid
WO2007087395A3 (en) UNSATURATED mTOR INHIBITORS
MY148723A (en) Use of pinolenic acid for the treatment of obesity
MX2012007375A (es) 3-ceto-n-propargil 1-aminoindano.
WO2008142055A3 (en) Antiviral agents
MX2012000414A (es) Derivados piridin-4-ilo.
WO2009016462A3 (en) Substituted bicyclolactam compounds
TNSN08173A1 (en) Dispersible tablets comprising deferasirox
SG170795A1 (en) Methods for improving the pharmacokinetics of hiv integrase inhibitors
WO2010066629A3 (en) Novel azaindoles
WO2006067392A3 (en) Indole derivatives for the treatment of tuberculosis
WO2008096820A1 (ja) ビフェニル誘導体
WO2005123049A3 (en) A pharmaceutical composition for increasing the mitochondrial genesis
TN2012000092A1 (en) Therapeutic agent for mood disorders
GEP20146168B (en) Pyrazinooxazepine derivatives
IL192190A0 (en) Process for the preparation of pharmaceutical salts of 3-o-(3&#39;,3&#39;-dimethylsuccinyl) betulinic acid
TN2012000105A1 (en) Spirolactam derivatives and uses of same
IL181267A0 (en) Vla-4 antagonists
GB2421442B (en) Tidal gas resuscitation monitor
WO2007120848A3 (en) Devices, systems and methods using magnetic force systems in the tongue
HK1131736A1 (en) A pharmaceutical composition having antipsychotic, antidepressant or antiepileptic activity with reduced side effect
WO2011058336A3 (en) Tablet comprising gum arabic
TN2012000093A1 (en) Therapeutic agent for anxiety disorders
MY145122A (en) Phenylacetic acid derivatives as cox-2 inhibitors